← Eichor
Study identifier: NCT07334288 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Retrolaminar Analgesia for LuMbar Surgery

Condition: Postoperative Pain · Lumbar Surgery · Back Pain Lower Back Chronic  ·  Sponsor: Universidad de los Andes, Chile

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This randomized controlled trial evaluates the effectiveness of ultrasound-guided retrolaminar nerve block in addition to standard multimodal analgesia for postoperative pain management in patients undergoing lumbar spine surgery. Fifty patients will be randomly assigned to receive either the retrolaminar block combined with standard pain management or standard pain management alone. The primary outcome is total opioid consumption in the first 24 hours after surgery. Secondary outcomes include pain intensity at multiple time points, time to first rescue analgesia, duration of sensory block, incidence of postoperative nausea and vomiting, length of hospital stay, patient satisfaction, and chronic pain development at 3 and 6 months follow-up.

This description comes directly from the study's public registry record.

Talk to the study team

Roberto Coloma, MD  ·  (56) 22 618 3100  ·  rcoloma@clinicauandes.cl

Nicolás Valls, MD, PhD  ·  +56 9 33741332  ·  nvalls@clinicauandes.cl

Always discuss trial participation with your own doctor first.

Locations (1)

Clínica Universidad de los Andes, ChileSantiago, Santiago Metropolitan, ChileRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07334288